167 related articles for article (PubMed ID: 31065705)
1. Predisposition of Wingless Subgroup Medulloblastoma for Primary Tumor Hemorrhage.
Reisinger D; Gojo J; Kasprian G; Haberler C; Peyrl A; Azizi AA; Mayr L; Chocholous M; Kool M; Czech T; Slavc I
Neurosurgery; 2020 Apr; 86(4):478-484. PubMed ID: 31065705
[TBL] [Abstract][Full Text] [Related]
2. Imaging Characteristics of Wingless Pathway Subgroup Medulloblastomas: Results from the German HIT/SIOP-Trial Cohort.
Stock A; Mynarek M; Pietsch T; Pfister SM; Clifford SC; Goschzik T; Sturm D; Schwalbe EC; Hicks D; Rutkowski S; Bison B; Pham M; Warmuth-Metz M
AJNR Am J Neuroradiol; 2019 Nov; 40(11):1811-1817. PubMed ID: 31649159
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical and nanoString-Based Subgrouping of Clinical Medulloblastoma Samples.
D'Arcy CE; Nobre LF; Arnaldo A; Ramaswamy V; Taylor MD; Naz-Hazrati L; Hawkins CE
J Neuropathol Exp Neurol; 2020 Apr; 79(4):437-447. PubMed ID: 32053195
[TBL] [Abstract][Full Text] [Related]
4. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort.
Waszak SM; Northcott PA; Buchhalter I; Robinson GW; Sutter C; Groebner S; Grund KB; Brugières L; Jones DTW; Pajtler KW; Morrissy AS; Kool M; Sturm D; Chavez L; Ernst A; Brabetz S; Hain M; Zichner T; Segura-Wang M; Weischenfeldt J; Rausch T; Mardin BR; Zhou X; Baciu C; Lawerenz C; Chan JA; Varlet P; Guerrini-Rousseau L; Fults DW; Grajkowska W; Hauser P; Jabado N; Ra YS; Zitterbart K; Shringarpure SS; De La Vega FM; Bustamante CD; Ng HK; Perry A; MacDonald TJ; Hernáiz Driever P; Bendel AE; Bowers DC; McCowage G; Chintagumpala MM; Cohn R; Hassall T; Fleischhack G; Eggen T; Wesenberg F; Feychting M; Lannering B; Schüz J; Johansen C; Andersen TV; Röösli M; Kuehni CE; Grotzer M; Kjaerheim K; Monoranu CM; Archer TC; Duke E; Pomeroy SL; Shelagh R; Frank S; Sumerauer D; Scheurlen W; Ryzhova MV; Milde T; Kratz CP; Samuel D; Zhang J; Solomon DA; Marra M; Eils R; Bartram CR; von Hoff K; Rutkowski S; Ramaswamy V; Gilbertson RJ; Korshunov A; Taylor MD; Lichter P; Malkin D; Gajjar A; Korbel JO; Pfister SM
Lancet Oncol; 2018 Jun; 19(6):785-798. PubMed ID: 29753700
[TBL] [Abstract][Full Text] [Related]
5. Clinical implications of medulloblastoma subgroups: incidence of CSF diversion surgery.
Schneider C; Ramaswamy V; Kulkarni AV; Rutka JT; Remke M; Tabori U; Hawkins C; Bouffet E; Taylor MD
J Neurosurg Pediatr; 2015 Mar; 15(3):236-42. PubMed ID: 25525930
[TBL] [Abstract][Full Text] [Related]
6. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study.
Schwalbe EC; Lindsey JC; Nakjang S; Crosier S; Smith AJ; Hicks D; Rafiee G; Hill RM; Iliasova A; Stone T; Pizer B; Michalski A; Joshi A; Wharton SB; Jacques TS; Bailey S; Williamson D; Clifford SC
Lancet Oncol; 2017 Jul; 18(7):958-971. PubMed ID: 28545823
[TBL] [Abstract][Full Text] [Related]
7. Approach to molecular subgrouping of medulloblastomas: Comparison of NanoString nCounter assay versus combination of immunohistochemistry and fluorescence in-situ hybridization in resource constrained centres.
Kaur K; Jha P; Pathak P; Suri V; Sharma MC; Garg A; Suri A; Sarkar C
J Neurooncol; 2019 Jul; 143(3):393-403. PubMed ID: 31104222
[TBL] [Abstract][Full Text] [Related]
8. Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis.
Clifford SC; Lusher ME; Lindsey JC; Langdon JA; Gilbertson RJ; Straughton D; Ellison DW
Cell Cycle; 2006 Nov; 5(22):2666-70. PubMed ID: 17172831
[TBL] [Abstract][Full Text] [Related]
9. MRI surrogates for molecular subgroups of medulloblastoma.
Perreault S; Ramaswamy V; Achrol AS; Chao K; Liu TT; Shih D; Remke M; Schubert S; Bouffet E; Fisher PG; Partap S; Vogel H; Taylor MD; Cho YJ; Yeom KW
AJNR Am J Neuroradiol; 2014 Jul; 35(7):1263-9. PubMed ID: 24831600
[TBL] [Abstract][Full Text] [Related]
10. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.
Zhukova N; Ramaswamy V; Remke M; Pfaff E; Shih DJ; Martin DC; Castelo-Branco P; Baskin B; Ray PN; Bouffet E; von Bueren AO; Jones DT; Northcott PA; Kool M; Sturm D; Pugh TJ; Pomeroy SL; Cho YJ; Pietsch T; Gessi M; Rutkowski S; Bognar L; Klekner A; Cho BK; Kim SK; Wang KC; Eberhart CG; Fevre-Montange M; Fouladi M; French PJ; Kros M; Grajkowska WA; Gupta N; Weiss WA; Hauser P; Jabado N; Jouvet A; Jung S; Kumabe T; Lach B; Leonard JR; Rubin JB; Liau LM; Massimi L; Pollack IF; Shin Ra Y; Van Meir EG; Zitterbart K; Schüller U; Hill RM; Lindsey JC; Schwalbe EC; Bailey S; Ellison DW; Hawkins C; Malkin D; Clifford SC; Korshunov A; Pfister S; Taylor MD; Tabori U
J Clin Oncol; 2013 Aug; 31(23):2927-35. PubMed ID: 23835706
[TBL] [Abstract][Full Text] [Related]
11. A simplified approach using Taqman low-density array for medulloblastoma subgrouping.
Cruzeiro GAV; Salomão KB; de Biagi CAO; Baumgartner M; Sturm D; Lira RCP; de Almeida Magalhães T; Baroni Milan M; da Silva Silveira V; Saggioro FP; de Oliveira RS; Dos Santos Klinger PH; Seidinger AL; Yunes JA; de Paula Queiroz RG; Oba-Shinjo SM; Scrideli CA; Nagahashi SMK; Tone LG; Valera ET
Acta Neuropathol Commun; 2019 Mar; 7(1):33. PubMed ID: 30832734
[TBL] [Abstract][Full Text] [Related]
12. Rapid diagnosis of medulloblastoma molecular subgroups.
Schwalbe EC; Lindsey JC; Straughton D; Hogg TL; Cole M; Megahed H; Ryan SL; Lusher ME; Taylor MD; Gilbertson RJ; Ellison DW; Bailey S; Clifford SC
Clin Cancer Res; 2011 Apr; 17(7):1883-94. PubMed ID: 21325292
[TBL] [Abstract][Full Text] [Related]
13. Real-time PCR assay based on the differential expression of microRNAs and protein-coding genes for molecular classification of formalin-fixed paraffin embedded medulloblastomas.
Kunder R; Jalali R; Sridhar E; Moiyadi A; Goel N; Goel A; Gupta T; Krishnatry R; Kannan S; Kurkure P; Deopujari C; Shetty P; Biyani N; Korshunov A; Pfister SM; Northcott PA; Shirsat NV
Neuro Oncol; 2013 Dec; 15(12):1644-51. PubMed ID: 24203893
[TBL] [Abstract][Full Text] [Related]
14. Imaging Biomarkers for Adult Medulloblastomas: Genetic Entities May Be Identified by Their MR Imaging Radiophenotype.
Keil VC; Warmuth-Metz M; Reh C; Enkirch SJ; Reinert C; Beier D; Jones DTW; Pietsch T; Schild HH; Hattingen E; Hau P
AJNR Am J Neuroradiol; 2017 Oct; 38(10):1892-1898. PubMed ID: 28798218
[TBL] [Abstract][Full Text] [Related]
15. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis.
Ramaswamy V; Remke M; Bouffet E; Faria CC; Perreault S; Cho YJ; Shih DJ; Luu B; Dubuc AM; Northcott PA; Schüller U; Gururangan S; McLendon R; Bigner D; Fouladi M; Ligon KL; Pomeroy SL; Dunn S; Triscott J; Jabado N; Fontebasso A; Jones DT; Kool M; Karajannis MA; Gardner SL; Zagzag D; Nunes S; Pimentel J; Mora J; Lipp E; Walter AW; Ryzhova M; Zheludkova O; Kumirova E; Alshami J; Croul SE; Rutka JT; Hawkins C; Tabori U; Codispoti KE; Packer RJ; Pfister SM; Korshunov A; Taylor MD
Lancet Oncol; 2013 Nov; 14(12):1200-7. PubMed ID: 24140199
[TBL] [Abstract][Full Text] [Related]
16. Medulloblastoma comprises four distinct molecular variants.
Northcott PA; Korshunov A; Witt H; Hielscher T; Eberhart CG; Mack S; Bouffet E; Clifford SC; Hawkins CE; French P; Rutka JT; Pfister S; Taylor MD
J Clin Oncol; 2011 Apr; 29(11):1408-14. PubMed ID: 20823417
[TBL] [Abstract][Full Text] [Related]
17. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas.
Kool M; Korshunov A; Remke M; Jones DT; Schlanstein M; Northcott PA; Cho YJ; Koster J; Schouten-van Meeteren A; van Vuurden D; Clifford SC; Pietsch T; von Bueren AO; Rutkowski S; McCabe M; Collins VP; Bäcklund ML; Haberler C; Bourdeaut F; Delattre O; Doz F; Ellison DW; Gilbertson RJ; Pomeroy SL; Taylor MD; Lichter P; Pfister SM
Acta Neuropathol; 2012 Apr; 123(4):473-84. PubMed ID: 22358457
[TBL] [Abstract][Full Text] [Related]
18. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables.
Ellison DW; Kocak M; Dalton J; Megahed H; Lusher ME; Ryan SL; Zhao W; Nicholson SL; Taylor RE; Bailey S; Clifford SC
J Clin Oncol; 2011 Apr; 29(11):1400-7. PubMed ID: 20921458
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of ARID1B, a tumor suppressor in the WNT subgroup medulloblastoma, activates multiple oncogenic signaling pathways.
Deogharkar A; Singh SV; Bharambe HS; Paul R; Moiyadi A; Goel A; Shetty P; Sridhar E; Gupta T; Jalali R; Goel N; Gadewal N; Muthukumar S; Shirsat NV
Hum Mol Genet; 2021 Aug; 30(18):1721-1733. PubMed ID: 33949667
[TBL] [Abstract][Full Text] [Related]
20. TP53 mutations in favorable-risk Wnt/Wingless-subtype medulloblastomas.
Lindsey JC; Hill RM; Megahed H; Lusher ME; Schwalbe EC; Cole M; Hogg TL; Gilbertson RJ; Ellison DW; Bailey S; Clifford SC
J Clin Oncol; 2011 Apr; 29(12):e344-6; author reply e347-8. PubMed ID: 21357788
[No Abstract] [Full Text] [Related]
[Next] [New Search]
